• Company
• Jemperli becomes 1st immunotherapy for endometrial cancer
• by Eo, Yun-Ho Dec 6, 2023 06:00am

• Company
• Erleada chases leader Xtandi in prostate cancer mkt
• by Kim, Jin-Gu Dec 6, 2023 06:00am

• Opinion
• [Reporter's View] Covid-19, endemic is not 'The End'
• by Eo, Yun-Ho Dec 6, 2023 06:00am

• Policy
• New price adj guidelines set for drugs with unstable supply
• by Lee, Tak-Sun Dec 6, 2023 06:00am

• Opinion
• [Desk’s View] On resolving the stock shortage of drugs
• by Lee, Tak-Sun Dec 5, 2023 05:49am

• Company
• AbbVie Korea strengthens its autoimmune disease pipeline
• by Eo, Yun-Ho Dec 5, 2023 05:48am

• Company
• Companies in KOR and abroad compete in Eylea biosimilar mkt
• by Son, Hyung-Min Dec 5, 2023 05:48am

• Policy
• MOHW will expand drugs subject to price adjustments
• by Lee, Tak-Sun Dec 5, 2023 05:48am

• Company
• Celltrion applies for US approval of its Prolia biosimilar
• by Chon, Seung-Hyun Dec 4, 2023 05:13am

• Policy
• Tagrisso and Leclaza complete drug pricing negotiations
• by Lee, Tak-Sun Dec 4, 2023 05:13am